Skip to content
Triangle logo TriangleGet started
← Study library

NCT00002550 · CITED IN SOURCE DOCUMENTS

Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2015-11-17

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy plus radiation therapy is more effective with or without surgery for lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combining cisplatin, etoposide, and radiation therapy with or without surgery in treating patients who have stage IIIA non-small cell lung cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically proven newly diagnosed, stage IIIA (T1-3, N2) non-small cell lung cancer * Eligible subtypes: * Adenocarcinoma * Large cell carcinoma * Squamous cell carcinoma * Nonlobar and nondiffuse bronchoalveolar cell carcinoma * Measurable or evaluable disease on chest x-ray and/or contrast CT scan * Contrast thoracic CT required to complete staging * Single primary bronchogenic tumor (no more than 1 parenchymal lung lesion) * Pleural effusions allowed if 1 of the following conditions is met: * Negative cytology on thoracentesis if effusions present before mediastinoscopy or exploratory thoracotomy * Effusion seen on CT scan but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance * Positive ipsilateral mediastinal node(s) with or without positive ipsilateral hilar nodes * Mediastinal nodes separate from primary lesion on CT scan or surgical exploration * Histologic or cytologic proof of N2 disease by thoracotomy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle, or fine needle aspiration under bronchoscopic or CT guidance * Nodal biopsy or aspiration waived if all of the following conditions are met: * Paralyzed left true vocal cord documented by bronchoscopy or indirect laryngoscopy * Nodes visible in Level 5 region on CT scan * Distinct primary lesion separate from nodes on CT scan * All mediastinal nodal involvement mapped (positive or negative) * No positive nodes in contralateral mediastinum (supraclavicular areas and higher) and neck * Mediastinoscopy, mediastinotomy, Chamberlain procedure, or thoracotomy required for nodes larger than 1 cm on contrast CT scan * Surgery waived if nodes negative or no larger than 1 cm on CT scan * Lymphadenopathy allowed if biopsy proof of a benign cause * No metastases by contrast CT or MRI scan of the brain, bone scan, CT scan of the lungs to exclude other ipsilateral or contralateral parenchymal lesions, and contrast CT scan of the upper abdomen including entire liver and adrenals * No hepatomegaly or splenomegaly by physical examination or CT scan unless documentation of a benign cause * No pericardial effusion * No superior vena cava syndrome * No prior diagnosis of lung cancer PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 90-100% (70-80% allowed if albumin at least 0.85 times lower limit of normal and weight loss no greater than 10% within 3 months before diagnosis) Hematopoietic: * White blood cell count (WBC) at least 4,000/mm\^3 OR * Granulocyte count at least 2,000/mm\^3 * Platelet count normal * Hemoglobin at least 10.0 g/dL (less than 8.5 g/dL allowed if no marrow involvement with tumor) Hepatic: * See Performance status * Bilirubin no greater than 1.5 times upper limit of normal (ULN)\* * Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) no greater than 1.5 times ULN\* NOTE: \* Unless documentation of a benign cause Renal: * Creatinine clearance at least 50 mL/min Cardiovascular: * No myocardial infarction within the past 3 months * No active angina * No unstable arrhythmia * No congestive heart failure Pulmonary: * Forced expiratory volume at one second (FEV1) at least 2.0 liters OR * Predicted postresection FEV1 at least 800 mL based on quantitative V/Q scan * Diffusion capacity of lung for carbon monoxide (DLCO) at least 50% predicted (corrected for hemoglobin) if pneumonectomy planned or likely after induction chemotherapy Other: * No clinically significant hearing loss unless willing to accept the potential of further loss * No symptomatic peripheral neuropathy * No peptic ulcer disease under active treatment * No other medical illness not controllable by appropriate medical therapy * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or ductal or lobular carcinoma in situ of the breast * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent colony-stimulating factors Chemotherapy: * No prior chemotherapy for lung cancer * No concurrent chemotherapy for another condition (such as arthritis) Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy for lung cancer Surgery: * See Disease Characteristics * No prior resection of primary tumor
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
    intervention Names
    1. Drug: cisplatin
    2. Drug: etoposide
    3. Procedure: conventional surgery
    4. Radiation: radiation therapy
    label
    RT + chemotherapy followed by surgery + chemotherapy
    type
    EXPERIMENTAL
  2. description
    Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
    intervention Names
    1. Drug: cisplatin
    2. Drug: etoposide
    3. Radiation: radiation therapy
    label
    RT + chemotherapy followed by chemotherapy + RT
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. RT + chemotherapy followed by chemotherapy + RT
    2. RT + chemotherapy followed by surgery + chemotherapy
    name
    cisplatin
    type
    DRUG
  2. arm Group Labels
    1. RT + chemotherapy followed by chemotherapy + RT
    2. RT + chemotherapy followed by surgery + chemotherapy
    name
    etoposide
    type
    DRUG
  3. arm Group Labels
    1. RT + chemotherapy followed by surgery + chemotherapy
    name
    conventional surgery
    type
    PROCEDURE
  4. arm Group Labels
    1. RT + chemotherapy followed by chemotherapy + RT
    2. RT + chemotherapy followed by surgery + chemotherapy
    name
    radiation therapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
429
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Median overall survival
    time Frame
    From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
secondary Outcomes
  1. measure
    Median Progression-free survival
    time Frame
    From randomization to date of death or last follow-up. Analysis occurs after patients have been potentially followed for 2.5 years.
  2. measure
    Patterns of local and distant failure
    time Frame
    From randomization to date of failure (local, regional or distant progression). Analysis occurs after patients have been potentially followed for 2.5 years.
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy plus radiation therapy is more effective with or without surgery for lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combining cisplatin, etoposide, and radiation therapy with or without surgery in treating patients who have stage IIIA non-small cell lung cancer.
detailed Description
OBJECTIVES: Primary * Compare the progression-free survival, median (2-year) survival, and long-term (5-year) survival in patients with newly diagnosed, stage IIIA (N2) non-small cell lung cancer treated with radiotherapy concurrently with cisplatin and etoposide with or without surgical resection. Secondary * Compare the patterns of local and distant failure in patients treated with these regimens. * Determine the relationship of tobacco use, alcohol use, and diet with toxicity of these regimens and outcome in both men and women. OUTLINE: This is a randomized, multicenter study. Patients are stratified by contralateral mediastinal sampling or biopsy (yes vs no), tumor stage (T1 vs T2 vs T3), and performance status (70-80% vs 90-100%). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive induction with cisplatin IV over 1 hour on days 1 and 8 and etoposide IV over 1 hour on days 1-5. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning within 24 hours of the first dose of chemotherapy, patients undergo induction radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients without local progression or distant metastases at 2-4 weeks after completion of course 2 undergo resection approximately 3-5 weeks after completion of course 2. All visible, accessible bronchopulmonary, hilar, and mediastinal lymph nodes are excised. The choice of surgical procedure (thoracotomy, lobectomy, or pneumonectomy with en bloc resection of tumor extending into the parietal pleura, chest wall, pericardium, or diaphragm) is at the discretion of the surgeon. Patients who undergo resection receive 2 additional courses of chemotherapy alone beginning 4-6 weeks postoperatively. Patients with unresectable disease or who are medically unfit for or refuse resection receive 2 additional courses of chemotherapy alone beginning immediately after completion of course 2. * Arm II: Patients undergo induction chemoradiotherapy as in arm I but do not undergo resection. Patients without local progression or distant metastases within 1 week before anticipated completion of induction radiotherapy receive 2 additional courses of chemotherapy beginning immediately after completion of course 2. Patients without local or distant progression after completion of course 4 undergo boost radiotherapy for 8 days. Patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 510 patients will be accrued for this study within 4.9 years.
Source references
references
  1. citation
    Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34. doi: 10.1016/j.ijrobp.2010.09.004. Epub 2010 Oct 25.
    pmid
    20980108
    type
    BACKGROUND
  2. citation
    Machtay M, Swann S, Komaki R, et al.: What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis. [Abstract] Lung Cancer 50 (Suppl 2): A-O-041, S17, 2005.
    type
    BACKGROUND
  3. citation
    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.
    pmid
    19632716
    type
    RESULT
  4. citation
    Albain KS, Swann RS, Rusch VR, et al.: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). [Abstract] J Clin Oncol 23 (Suppl 16): A-7014, 624s, 2005.
    type
    RESULT
  5. citation
    Albain KS, Scott CB, Rusch VR, et al.: Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2497, 2003.
    type
    RESULT
  6. citation
    Turrisi AT, Scott CB, Rusch VR, et al.: Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309). [Abstract] Int J Radiat Oncol Biol Phys 57 (2 Suppl): S125-6, 2003.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-1b1ec6f63a7eebaa421b
      requested nct id
      NCT00002550
      primary nct id
      NCT00002550
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      payload sha256
      02709424f5a66836cc1ead52c2cd83b42e1312229c5c6cd9c7b0dcb10f49ab0b
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-1b1ec6f63a7eebaa421b
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00002550
      occurrences
      1. context exact
        47" tabindex="-1">Evidence (neoadjuvant chemoradiation therapy):</p> <div class="pdq-content-list"><ol id="_484648"><li> The <a href="/clinicaltrials/NCT00002550">Intergroup-0139</a> trial (NCT00002550) compared chemoradiation therapy alone with neoadjuvant chemoradiation followed by surgery in 396 patients with stage
        end
        271187
        exact text
        NCT00002550
        start
        271176
      2. context exact
        hemoradiation therapy):</p> <div class="pdq-content-list"><ol id="_484648"><li> The <a href="/clinicaltrials/NCT00002550">Intergroup-0139</a> trial (NCT00002550) compared chemoradiation therapy alone with neoadjuvant chemoradiation followed by surgery in 396 patients with stage IIIA (N2) NSCLC.[<a href="#cit/section_9.
        end
        271228
        exact text
        NCT00002550
        start
        271217
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.782436+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
      source title
      Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 15, 2025
        datetime
        2025-05-15T12:00:00Z
        display
        May 15, 2025

    Preserved source evidence · Not medical advice